Long-term efficacy of metformin in obese PCOS: longitudinal follow up of retrospective cohort.
Long-term efficacy of metformin in polycystic ovarian syndrome (PCOS) apart from in those with impaired glucose tolerance or diabetes remains unproven. We aimed to evaluate the impact of metformin in overweight-obese patients with PCOS and normal baseline glycemic homeostasis. 10 year longitudinal follow up of retrospective cohort comprising of 159 patients with PCOS defined by Rotterdam criteria, BMI≥ 25kg/m2 and normal initial glucose homeostasis (age 28.4±6.4 years, BMI 34.9±6.6 kg/m2) that had been receiving metformin 1000 mg BID. Collection data contained 6085time-points including anthropometric, hormonal and metabolic parameters. After the 1st year body mass(BM) decreased for 3,9±6.8kg (p<0.001) and remained stable during the following 3 years. Menstrual frequency (MF) increased for3.0±3.9 bleeds/year (p<0.001) after 1st year to over 11 bleeds/year in the following years. The total testosterone and androstenedione decreased for 15.4±47.9% and 11.3±46.4% within 1st year, with further decrease in total testosterone and androstenedione for 37.8±61.8 and 24.8±40.5% at the 5th year of the follow up. The total conversion rate to prediabetes and diabetes was extremely low throughout observation period. Less than 25% of patients continued with metformin for more than five years with further dropout to only 6% on metformin therapy at the 10th year of follow up. Long-term metformin treatment of overweight-obese women with PCOS and normal baseline glycemic homeostasis resulted in reduction and stabilization of BM, improvements of MF and androgen profile and low conversion rate to diabetes.